Ces radiol. 2026, 80(1):38-45 | DOI: 10.55095/CesRadiol2026/012

Imaging of somatostatin receptor density and physiological variability of 68Ga-edotreotide distribution in tissues - significance for evaluation of findingsReview article

Marika Looseová, Martina Odvody, Eva Ferdová, Táňa Baráková, Jan Pernický, Jiří Ferda
Klinika zobrazovacích metod LF UK a FN, Plzeň
Korespondenční adresa:
PharmDr. Marika Looseová
Klinika zobrazovacích metod LF UK A FN
alej Svobody 80, 323 00 Plzeň
Podpořeno projektem MZ ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a projektem COOPERATIO, basic sciences Univerzity Karlovy.
Konflikt zájmů: žádný.

V souhrnném článku jsou diskutovány subtypy jednotlivých somatostatinových receptorů, funkce a struktura somatostatinu a jeho účinek na receptory. V článku se popsán způsob přípravy radiofarmaka 68Ga-edotreotidu, jeho distribuce a zejména vazba na tkáně, které jsou fyziologicky vybaveny somatostatinovými receptory.

Keywords: somatostatin, 68Ga-edotreotid, DOTATOC, pozitronová emisní tomografie.

Accepted: February 15, 2026; Published: May 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Looseová M, Odvody M, Ferdová E, Baráková T, Pernický J, Ferda J. Imaging of somatostatin receptor density and physiological variability of 68Ga-edotreotide distribution in tissues - significance for evaluation of findings. Ces radiol. 2026;80(1):38-45. doi: 10.55095/CesRadiol2026/012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somaostatin receptors, Digestion 2000; 67(Suppl 1): 27-32. Go to original source... Go to PubMed...
    2. Watanabe N, Nakanishi Y, Kinukawa N, et al. Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes. Acta Histochem Cytochem. 2014; 47(5): 219-229. Go to original source... Go to PubMed...
    3. Priyadashini S, Allison DB, Chauhan A. Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review. Pharmaceutics, 2022; 14(7): 1394. doi: 10.3390/pharmaceutics14071394 Go to original source... Go to PubMed...
    4. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33(4): 460-466. Go to original source...
    5. Miederer M, Seidl S, Buck A, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36(1): 48-52. Go to original source... Go to PubMed...
    6. Velikyan I, Sundin A, Eriksson Bet L. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol. 2010; 37(3): 265-275. Go to original source... Go to PubMed...
    7. Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252(5): 850-856. Go to original source... Go to PubMed...
    8. Zhang H, Moroz MA, Serganova I, et al. Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. J Nucl Med. 2011; 52(1): 123-131. Go to original source... Go to PubMed...
    9. Boy C, Heusner TA, Poeppel TD, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011; 38(7): 1224-1236. Go to original source... Go to PubMed...
    10. Chereau E, Durand L, Frati A, et al. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. Anticancer Res. 2013; 33(8): 3015-1019.
    11. Asti M, Iori M, Capponi PC, et al. Development of a simple kit-based method for preparation of pharmaceutical-grade ⁶⁸Ga-DOTATOC. Nucl Med Commun. 2015; 36(5): 502-510. Go to original source... Go to PubMed...
    12. Cingarlini S, Ortolani S, Salgarello M, et al. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. Pancreas 2017; 46(1): 42-47. Go to original source...
    13. Lococo F, Rapicetta C, Mengoli MC, et al. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. Interact Cardiovasc Thorac Surg. 2019; 28(6): 957-960. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content